Radiotherapy in patients with connective tissue diseases

This is the author's manuscript

Original Citation:
Radiotherapy in patients with connective tissue diseases / Giaj-Levra, Niccolò; Sciascia, Savino; Fiorentino, Alba; Fersino, Sergio; Mazzola, Rosario; Ricchetti, Francesco; Roccatello, Dario; Alongi, Filippo. - In: LANCET ONCOLOGY. - ISSN 1470-2045. - 17:3(2016), pp. e109-e117.

Availability:
This version is available http://hdl.handle.net/2318/1557564 since 2019-02-13T15:13:11Z

Published version:
DOI:10.1016/S1470-2045(15)00417-9

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in LANCET ONCOLOGY, 17 (3), 2016, 10.1016/S1470-2045(15)00417-9.

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.

(2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.

(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), 10.1016/S1470-2045(15)00417-9

The publisher's version is available at:
http://linkinghub.elsevier.com/retrieve/pii/S1470204515004179

When citing, please refer to the published version.

Link to this full text:
http://hdl.handle.net/2318/1557564

This full text was downloaded from iris - AperTO: https://iris.unito.it/
Radiotherapy in patients with connective tissue diseases

Giaj-Levra N1, Sciascia S2, Fiorentino A3, Fersino S3, Mazzola R3, Ricchetti F3, Roccatello D2, Alongi F3.

1 Radiation Oncology Department, Sacro Cuore Hospital, Negrar-Verona, Italy. Electronic address: niccolo.giajlevra@sacrocuore.it.

2 Center of Research of Immunopathology and Rare Diseases–Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Torino, Italy, Turin, Italy.

3 Radiation Oncology Department, Sacro Cuore Hospital, Negrar-Verona, Italy.

Summary
The decision to offer radiotherapy in patients with connective tissue diseases continues to be challenging. Radiotherapy might trigger the onset of connective tissue diseases by increasing the expression of self-antigens, diminishing regulatory T-cell activity, and activating effectors of innate immunity (dendritic cells) through Toll-like receptor-dependent mechanisms, all of which could potentially lead to breaks of immune tolerance. This potential risk has raised some debate among radiation oncologists about whether patients with connective tissue diseases can tolerate radiation as well as people without connective tissue diseases. Because the number of patients with cancer and connective tissue diseases needing radiotherapy will probably increase due to improvements in medical treatment and longer life expectancy, the issue of interactions between radiotherapy and connective tissue diseases needs to be clearer. In this Review, we discuss available data and evidence for patients with connective tissue diseases treated with radiotherapy.

Introduction
Connective tissue diseases are a heterogeneous group of autoimmune rheumatic diseases characterised by immune system dysregulation and the development of autoantibodies. Patients typically alternate between active or symptomatic periods and non-active or quiescent phases. Connective tissue diseases have historically been considered an absolute or relative contraindication to radiotherapy because of the hypothesis of a greater risk of severe radiotherapy-related acute and late complications. Few reports have been made of the outcomes of patients with newly diagnosed connective tissue diseases (or exacerbation of pre-existing disease) who need radiotherapy (Table 1 and Table 2).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 Although an analysis of the little available data shows that risk of radiotherapy toxicity in patients with connective tissue diseases seems to be based largely on anecdotal evidence, radiation oncologists remain hesitant. In 1998, the American College of Radiology22 concluded that, “a history of collagen vascular disease is a relative contraindication to breast conservation treatment because published reports indicate that such patients tolerate irradiation poorly. Most radiation oncologists will not treat patients with scleroderma or active systemic lupus erythematosus, considering either an absolute contraindication.” Thus, radiotherapy has been underused in patients with connective tissue diseases who have cancer.16

With improved medical treatments, prognosis for patients with connective tissue diseases has improved. The 5-year survival in systemic lupus erythematosus has increased from about 40% in the 1950s, to 90% in the 1980s, to more than 90–95% nowadays.23 Therefore, a higher number of patients with connective tissue diseases are expected to be diagnosed with cancer and will potentially be eligible for oncological treatment, including radiotherapy. Substantial improvements have been made in radiation technology, including the development of intensity-modulated radiotherapy and image-guided radiotherapy. These techniques are available in clinical practice, potentially minimising acute and late local side-effects. Thus, new radiotherapy techniques could be considered feasible even in patients with connective tissue diseases who have cancer. In this Review, we analyse evidence and discuss the available data for radiotherapy in patients with connective tissue diseases.

Connective tissue diseases, cancer environments, and radiation interactions
Connective tissue diseases are chronic and debilitating autoimmune disorders that cause substantial morbidity and mortality and disproportionately affect women. These diseases include rheumatoid arthritis, systemic sclerosis, scleroderma, systemic lupus erythematosus, dermatomyositis, and vasculitis. Connective tissue diseases often develop after environmental triggering via cellular pathways in genetically susceptible individuals with disease-associated polymorphisms.24 However, the specific cellular and molecular mechanisms leading to connective tissue diseases, and factors that establish involved organs are involved, are poorly understood.
Associations between connective tissue diseases and cancer are being increasingly investigated. Links between them are multifaceted and have different relationships in terms of frequency, timing, and type of cancers. Several studies have highlighted the dynamic and bidirectional interactions occurring at the cancer–immune system interface that might be relevant to the origins of autoimmunity. Data for patients with systemic sclerosis and concomitant cancer suggest that, in some cases, autoimmunity might be triggered by an autoantigen mutation in the patient's cancer. Also, connective tissue diseases might cause changes in immune function that could be affected by immunosuppressive therapy. Although the evidence was not overwhelming, some investigators have reported that these changes in immune function did affect radiotherapy toxicity. This bidirectional hypothesis was based on the idea that some connective tissue diseases share a common pathological pathway of vascular obliteration and fibrosis due to heightened inflammation and a clinical pattern of possible systemic involvement. The potential for radiotherapy to augment these pathological changes became a topic of investigation. Radiotherapy acutely affects early responding tissues, such as the basal dermis and oral and gastric mucosa, by reducing proliferation. Radiation-induced obliteration of capillaries and small vessels is also well documented. In patients with connective tissue diseases, these acute effects might act in conjunction with immune-related damage caused by immune complex deposition, complement cascade activation, and infiltrating inflammatory cells (figure 1). Such common targeting might be additive to typical radiation-induced acute tissue injuries. The additive injury induced by both radiation and the pre-existing connective tissue diseases might also help to explain the potentially increased late effects noted in some of these patients after radiotherapy. Radiotherapy might trigger the onset of connective tissue diseases by enhancing the expression of self-antigens (e.g., from apoptotic cell debris), diminishing regulatory T-cell activity, and activating effectors of innate immunity such as dendritic cells through Toll-like receptor-dependent mechanisms, all of which could potentially lead to a break of immune tolerance. This potential mechanism has raised a debate among radiation oncologists about whether patients with connective tissue diseases tolerate radiation as well as people with no connective tissue disease.

Experimental evidence supports the hypothesis that the immune system is able to repress tumour cells and that immune surveillance has a key role in the identification and elimination of cancer cells. Three different phases have been described in the interaction between cancer cells and the immune system: elimination (which is still considered the cornerstone in the immune surveillance process), equilibrium between the immune system and cancer cells, and escape. Immune surveillance is considered a complex process involving different immune system cells—i.e., CD8 cells, natural killer cells, CD4 cells, macrophages, and B lymphocytes. After radiotherapy, the disruption of the tissue architecture is associated with changes in blood flow (zones with hyperperfusion and hypoxia) and lymphatic function and an increase in interstitial pressure. Additionally, irradiation of the tumour and its microenvironment is associated with the proliferation of inflammatory signals detected by the immune system. The resulting production of cytokines and chemokines then attracts antigen-presenting cells (dendritic cells) that, after uptake of tumour-associated antigens, cause CD8 activation involved in tumour killing (figure 1). Evidence is also increasing that inflammation contributes to cancer development and that cancer cells use inflammatory mechanisms to prevent immune-system activation and to protect the tumour from immune attack (equilibrium and escape phases). Moreover, inflammatory elements (such as chemokines and interleukins) released by tumour cells promote infiltration, progression of disease, and metastases (figure 2). Various mechanisms might exist that exacerbate the pathophysiological response induced by radiation exposure in patients with connective tissue diseases. One potential mechanism includes the overexpression of profibrotic cytokines, such as transforming growth factor β (TGFβ) and interleukin 1. Radiation injury in healthy tissues is usually characterized by the appearance of a fibrous exudate within the stroma and by deposition of extracellular matrix components, including collagen, through myofibroblasts produced by fibroblast activation and differentiation. In some connective tissue diseases (such as systemic sclerosis) in which TGFβ concentrations are already increased, late effects after radiotherapy might be more evident. Another potential mechanism involves radiation microvascular damage in a context of vasculitis, leading to increased late effects and reduced tolerance to treatment. After radiation, endothelial cell injury and tissue hypoxia stimulate the recruitment into the tissue of inflammatory circulating cells, such as macrophages, which are a source of profibrotic mediators, including TGFβ1. Additionally, increased concentrations of proangiogenesis factors (e.g., VEGF) as a result of vascular damage and leakage of vessels in response to radiotherapy could exacerbate late effects such as dermal atrophy, telangiectasia, necrosis, and fibrosis. Finally, radiation-induced damage to basement membranes causes this to become a target tissue, leading to increased autoimmunity.

Preclinical studies and case reports
Some studies have used in-vitro sensitivity to radiation in lymphocytes from patients with connective tissue diseases to assess risk indicators for radiation-related side-effects. Others have used pulsed-field
gel electrophoresis to quantify the initial radiation-induced DNA double-strand breaks in peripheral lymphocytes from 52 patients with systemic lupus erythematosus. Systemic lupus erythematosus did not confer a higher intrinsic risk of radiosensitivity when compared with 48 healthy participants without connective tissue diseases.41 In another study,43 the same investigators carried out an in-vitro evaluation of the repair of mainly single-stranded DNA breaks after peripheral blood radiation of 48 children with systemic lupus erythematosus, systemic sclerosis, juvenile rheumatoid arthritis, and dermatomyositis. Greater DNA damage and a delay in DNA repair were noted in the children with connective tissue diseases group than in healthy children.43 Another in-vitro study that used tritiated thymidine incorporation assays showed that patients with active systemic lupus erythematosus had increased radiotherapy-related lymphocytic sensitivity when compared with healthy patients when irradiated with 60Co-γ photons between 0 Gy and 10 Gy, resulting in a potentially higher probability of radiation toxicity.42 Similarly, immune system changes, which can affect radiosensitivity, are being investigated. Among others, Budach and colleagues44 investigated the possibly abnormal reaction to high radiation doses in two groups of germline mutation-carrying mice, one with severe combined immunodeficiency (SCID; even though it is not classified as a connective tissue disease) and one that had normal radiation sensitivity (C3H). The lethal dose for 50% of the irradiated animals after single-dose whole-body irradiation was lower for SCID mice than for C3H mice, as was the radiation dose that was needed to achieve 50% local control and tumour growth delay, thus confirming that abnormal radiation sensitivity was observed in SCID mice.44 A possible mechanism correlated with increased sensitivity of SCID tumour cell lines is the inability of the tumour cells to overcome their genetic deficiency in DNA double-strand break repair in SCID fibroblasts.45 More than 300 cases involving patients with connective tissue diseases have been published reporting toxicity after radiotherapy and several early and late radiotherapy-related complications, including some deaths, have also been reported.2, 5, 7, 10 and 46 The first two severe events in patients with connective tissue diseases given radiotherapy were noted in the late 1960s.47 and 48 In one case, a patient with systemic lupus erythematosus who had lymphoma died of heart failure 1 year after radiotherapy to the mediastinal and retroclavicular nodes (20 Rad [20 Gy] and 39 Rad [39 Gy], respectively, with 60Co).47 whereas the second patient, who had facial lupus, developed radiotherapy-correlated osteomyelitis of the maxilla.48 However, no data about radiotherapy dose or modality were provided. Teo and colleagues1 assessed the radiation toxicity profiles of ten patients with a diagnosis of early-stage nasopharyngeal carcinoma and dermatomyositis (table 1). At a median follow-up of 51–8 months, all patients had subcutaneous fibrosis and xerostomia, two patients had radiation skin necrosis, and one patient had a VI and XII cranial nerve deficit.1 However, no information was provided about radiotherapy dose and techniques.

Fleck and colleagues2 published a study of nine patients with breast cancer (four women with a pre-existing connective tissue disease and five who developed a connective tissue disease after radiotherapy). Eight received radiotherapy using 60Co with a prescription dose of 40–50 Gy and an electron boost on the tumour bed of 5–15 Gy. Three patients with a pre-existing connective tissue disease reported a severe toxicity profile: the first case involved moist desquamation and brachial plexopathy; the second case showed soft-tissue necrosis needing chest-wall resection, rib fractures, and pulmonary fibrosis; and the third patient had soft-tissue necrosis, bronchopleural–cutaneous fistula, and osteonecrosis of the clavicle, sternum, and rib. None of the patients with a new diagnosis of connective tissue diseases after radiotherapy had severe complications.2 According to McCormick,49 to reduce the side-effects in patients with connective tissue disease and breast cancer, a more aggressive local surgery and systemic therapy, in particular for younger women (<40 years), was better than breast-conserving surgery followed by radiation. More recently, accelerated partial breast irradiation by either brachytherapy or intraoperative radiotherapy has been considered an alternative experimental option for the treatment of early-stage breast cancer in women with a history of connective tissue diseases. Dragun and colleagues9 published a report of nine patients with connective tissue diseases with breast cancer given accelerated partial breast irradiation via high-dose brachytherapy; toxicity and cosmetic profiles were reported as satisfactory. Indeed, the authors concluded that it might not be necessary to exclude patients with connective tissue diseases from clinical trials of accelerated partial breast irradiation. As confirmation, Turesson and colleagues6 reported that autoimmune disease did not increase the risk of skin telangetasia in 35 patients who received radiotherapy for breast cancer. Finally, Lowell and colleagues10 published data on the use of a very high dose of radiation delivered with gamma knife for brain metastases in 14 patients with connective tissue diseases, and reported no grade 3 or 4 toxicity (table 1).

In conclusion, in-vitro studies and clinical case reports describe a narrow and heterogeneous picture for patients with connective tissue diseases who receive radiotherapy. Despite these data limitations, more recently published data show that patients with connective tissue diseases seem to be less affected by toxicity than are healthy individuals and case reports (table 1).
Retrospective and controlled studies

To our knowledge, no randomised controlled study has assessed whether patients with connective tissue diseases are more likely to develop acute or late radiotherapy-related toxicity. However, we retrieved 11 case series. In a retrospective analysis, Morris and Powell reported a large series of 209 patients with connective tissue diseases given radiotherapy with a median radiation dose of 45 Gy (range 13–82) between 1960 and 1995. After a median follow-up of 6 years, clinically significant acute side-effects (Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group RTOG/ECOG Early Morbidity Scoring Scale of more than three) were similar in patients with and without rheumatoid arthritis (both 12%). At 5 years, the risk of late morbidity for patients with rheumatoid arthritis was 6%, similar to the rate for the healthy population generally, whereas for patients without rheumatoid arthritis it was 21% (p=0.0002). The most highly presented connective tissue disease after rheumatoid arthritis was systemic lupus erythematosus, with 25 patients (12%). No correlation between dose, fraction size, irradiated volume, and late effects were reported.

Similar results were reported in a matched-control study of 61 patients with connective tissue diseases. The number of acute reactions after radiotherapy in the connective tissue diseases group was only slightly higher than in the matched-control group, with grade 3 or greater acute toxicity noted in seven patients in the connective tissue diseases group and four in the matched-control group. Patients with systemic lupus erythematosus had an increase in the number of acute reactions due to radiation (36% of patients with systemic lupus erythematosus vs 18% in the control group, p=0.5), whereas patients with rheumatoid arthritis had an increase in late complications (24% vs 5%; p=0.125). Nevertheless, the study showed no significant differences in acute and late toxicity complications between groups.

Chen and colleagues reported no significant differences in acute complications after breast cancer radiotherapy between a group of 36 women with connective tissue diseases and a matched-control group (14% vs 8%, respectively; p=0.40), but did note a significant difference in late toxicity in those patients with connective tissue diseases (17% vs 3%; p=0.0095). However, when the investigators stratified patients by specific autoimmune disease, they found a significant difference only in four patients with scleroderma. Phan and colleagues assessed 76 patients who received radiation for cancer (38 patients with connective tissue diseases and 38 in the control group) and did not show any significant differences in terms of acute or late complications between groups. Increased risk of radiation complications was reported in patients with scleroderma (n=4).

In another study, Lin and colleagues reported toxic effects in 73 patients with connective tissue diseases given radiotherapy. No differences were noted in acute toxicity between patients with connective tissue diseases and those in the control group. However, patients with a diagnosis of connective tissue diseases had a significantly higher incidence of late toxicity compared with the control group (29% vs 14%, respectively; p=0.01), with a non-significant increase in severe late toxicity (9% vs 4%; p=0.079). Patients with diagnosed connective tissue diseases who received radiation to the pelvis had a higher probability of severe toxicity reactions (grade 3 or higher); furthermore, the incidence of severe late toxicity was higher in patients with a diagnosis of systemic lupus erythematosus and scleroderma than in the control group. Gold and colleagues retrospectively analysed the toxicity profile of 41 patients with connective tissue diseases given radiation for cancer (20 patients with systemic sclerosis and 21 patients with systemic lupus erythematosus). Patients were divided into high-severity and low-severity connective tissue diseases on the basis of the number of involved organs. Univariate analysis showed a significant increase in the risk of any grade toxicity for patients with high-severity connective tissue diseases compared with those with low-severity connective tissue diseases (p=0.006), although no differences in grade 3 or higher toxicity were found between the two groups (p=0.56). Despite the small number of enrolled patients, the severity of connective tissue diseases could be considered as an important factor in the prediction of treatment tolerability. Nonetheless, the severity of connective tissue diseases was not a clear contraindication to radiotherapy.

Varga and colleagues reported on the toxicity profile of four patients with systemic sclerosis who were given radiotherapy. All patients had cutaneous and subcutaneous late toxicity, visceral fibrotic reactions at the radiation site, and severe skin toxicity and fibrosis extending beyond the radiation field involving internal organs. Three of the four patients subsequently died, two from bowel obstruction and one from pneumonia.

Liu and colleagues planned a prospective study to investigate the effect of neoadjuvant androgen-deprivation therapy and radiotherapy in men with prostate cancer. A subanalysis showed that 15 of the men had a connective tissue disease and that these patients had a greater frequency of late genitourinary grade 2 toxicities compared with healthy men (relative risk 3.98; p=0.007).

As previously stated, several studies have reported radiotherapy-related toxicity profiles in patients with a range of connective tissue diseases (Table 1 and Table 2). Nevertheless, only a few of the studies focused on patients with scleroderma and systemic lupus erythematosus, with contentious conclusions about radiotherapy toxicity. Gold and colleagues assessed the toxicity profiles of 20 patients with scleroderma and cancer who had been treated with
radiotherapy or brachytherapy or both, with or without concurrent chemotherapy. Univariate analysis showed a significant association between acute toxicity, radiotherapy dose, and increased scleroderma involvement of organs. For late side-effects, negative antinuclear antibody serology was correlated with a higher probability of toxicity. None of the analysed pretreatment and treatment variables were correlated with severe acute and late toxicity.17 There have been no further reports to confirm severe acute and late complication profiles in this specific setting.7, 8 and 10 Rakfal and Deutsch7 described data for six patients who had a diagnosis of systemic lupus erythematosus and different malignancies with various radiotherapy doses, reporting no unexpected severe acute or late side-effects. Khoo and colleagues8 reported no relevant acute or late complications in two patients with anal cancer with systemic lupus erythematosus taking concomitant immunosuppressive therapy who were treated with combined chemoradiotherapy (60Co and external-beam radiotherapy). One of the most important reports was published by Pinn and colleagues,20 which included 21 patients with systemic lupus erythematosus who received a total of 35 consecutive courses of radiotherapy. Of the 17 patients who were evaluable for late toxicity, four patients (24%) had a grade 3 or higher toxicity. The presence of renal involvement according to the American Rheumatism Association criteria was correlated with an increased risk of any grade of late toxicity (p<0·006). Univariate analysis established a correlation between acute toxicity and total dose (>49·8 Gy), treatment sites, and curative intent for treatment. Brachytherapy was used in one treatment course, 2D radiotherapy in 30 courses, 3D conformal radiotherapy in three, and intensity-modulated radiotherapy in one. Moreover, absence of photosensitivity (p<0·02), absence of arthritis (p<0·03), and presence of a malar rash (p<0·04) were correlated with an increased risk of grade 3 or greater acute toxicity. No specific association between technique and late toxicity was noted. Radiation dose prescription, radiation techniques, and anatomical site (ie, abdomen, pelvis, breast, brain, neck, and chest) were associated with a high risk of any late toxicity. In conclusion, the small number of described cases and the heterogeneity of the connective tissue disease seem to strongly affect the statistical power of these studies, thus limiting the possibility to show any robust association between radiation toxicity and connective tissue diseases, and confirming that radiotherapy is frequently withheld unjustly to treat patients with connective tissue diseases.16, 19 and 21

Clinical solutions and future perspectives
Various treatment strategies have been considered for patients with connective tissue diseases to reduce the risk of toxicity during or after radiotherapy such as avoiding concomitant treatment or reducing dose prescription. Although the use of chemoradiotherapy is considered the gold standard in many cases, multimodality treatment in patients with connective tissue diseases could be correlated with a more severe toxicity profile than single-modality treatment, thereby affecting its feasibility.4, 12, 19 and 50 In radiotherapy, the radiation dose could be reduced to lower the toxicity profile, but this could impair effectiveness.12, 28, 44 and 51 However, Delanian and colleagues52 reported that reducing radiation dose (from 65 Gy to 40 Gy) in patients with connective tissue diseases (one with lung cancer and two with anal–rectal cancer) resulted in complete remission, although side-effects were observed at the radiation site. Some investigators have postulated that hyperactivation of the immune system by tumour cells makes patients with connective tissue diseases more sensitive to radiation than others.53 and 54 Another strategy is changing dose fractionation schedules or reducing treatment volume, which might decrease toxicity complications.2, 12, 28, 40, 51, 52 and 54 Nevertheless, a crucial question still remains—is it really necessary to modify radiotherapy features to decrease toxicity in patients with connective tissue diseases? The most common radiotherapy approach is to use external beams to deliver ionising radiation. In the past few decades, most departments have replaced their 60Co machines with the more precise linear accelerator. Despite modern radiotherapy now being available, most reports of patients with connective tissue diseases involve obsolete and unsatisfactory technologies including 2D radiotherapy. Intensity-modulated radiotherapy and stereotactic ablative radiotherapy have allowed radiation oncologists to prescribe higher dose prescriptions to targets when useful or required. Intensity-modulated radiotherapy is considered an advancement of 3D-conformal radiotherapy that targets the radiation dose into the tumour, thus minimising the exposure of healthy tissue in several anatomical regions. Intensity-modulated radiotherapy is considered the most appropriate technique in head and neck cancers and in most pelvic tumours, including prostate cancer. In this disease, intensity-modulated radiotherapy decreased long-term toxicity with no negative effect on overall survival when compared with 3D-conformal radiotherapy.54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 and 66. Stereotactic ablative radiotherapy is a novel radiotherapy method that delivers a very high dose of radiation (in a single or a few fractions) with high precision to the tumour, thus maximising the sparing of surrounding normal tissue. Several retrospective and prospective stereotactic ablative radiotherapy studies have shown promising results in terms of local tumour control and survival in some settings, including in early non-small-cell lung cancer.67 Moreover, image-guided radiotherapy based on daily patient set-up position verification allowed better definition of the tumour target to reduce and ultimately eliminate uncertainties. To our knowledge, no randomised controlled trials using image-guided radiotherapy have assessed toxicity and efficacy in patients with connective tissue disease. Hence, the promising, modern techniques
could improve radiotherapy tolerability, especially in challenging clinical situations, as well as in patients with connective tissue diseases and cancer.68 and 69

Conclusion

The data that are currently available from case series and a few retrospective studies are still not enough to support a specific contraindication for radiotherapy in patients with connective tissue diseases. Nevertheless, a cautious approach for patients with active connective tissue diseases seems to be reasonable. Moreover, the recent implementation of new radiotherapy approaches could be promising to improve the feasibility and tolerability of radiotherapy in some patients with cancer, including those with connective tissue diseases. Further well designed prospective studies, which also assess the most appropriate total dose and fractionation schedules, will probably help to overcome the unresolved concerns about radiotherapy indication for patients with connective tissue diseases.

References

<table>
<thead>
<tr>
<th>Tumour type</th>
<th>Patients with connective tissue disease (n)</th>
<th>Type of connective tissue disease</th>
<th>Increase in severe acute toxicity</th>
<th>Increase in severe late toxicity</th>
<th>Treatment</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head and neck</td>
<td>10</td>
<td>Dermatomyositis</td>
<td>Yes</td>
<td>Yes</td>
<td>External-beam radiotherapy</td>
<td>Effect</td>
</tr>
<tr>
<td>Breast</td>
<td>9</td>
<td>Mixed</td>
<td>Yes</td>
<td>Yes</td>
<td>External-beam radiotherapy</td>
<td>Effect</td>
</tr>
<tr>
<td>Mixed</td>
<td>4</td>
<td>Progressive systemic sclerosis</td>
<td>No</td>
<td>Yes</td>
<td>External-beam radiotherapy</td>
<td>Effect</td>
</tr>
<tr>
<td>Head and neck</td>
<td>2</td>
<td>Mixed</td>
<td>Yes</td>
<td>No</td>
<td>Concurrent chemotherapy and external-beam radiotherapy</td>
<td>Inconclusive*</td>
</tr>
<tr>
<td>Cervix</td>
<td>5</td>
<td>Mixed</td>
<td>Yes</td>
<td>No</td>
<td>External-beam radiotherapy and brachytherapy</td>
<td>Effect</td>
</tr>
<tr>
<td>Breast</td>
<td>35</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>NA</td>
<td>No effect</td>
</tr>
<tr>
<td>Mixed</td>
<td>6</td>
<td>Systemic lupus erythematosus, discoid lupus erythematosus</td>
<td>No</td>
<td>No</td>
<td>External-beam radiotherapy</td>
<td>No effect</td>
</tr>
<tr>
<td>Anal cancer</td>
<td>2</td>
<td>Systemic lupus erythematosus</td>
<td>No</td>
<td>No</td>
<td>Concurrent chemotherapy and external-beam radiotherapy</td>
<td>No effect</td>
</tr>
<tr>
<td>Breast</td>
<td>9</td>
<td>Mixed</td>
<td>No</td>
<td>No</td>
<td>Intraoperative radiotherapy and brachytherapy</td>
<td>No effect</td>
</tr>
<tr>
<td>Brain metastases</td>
<td>14</td>
<td>Mixed</td>
<td>No</td>
<td>No</td>
<td>Gamma knife</td>
<td>No effect</td>
</tr>
</tbody>
</table>

Table 1.
Patient characteristics and findings from selected case studies of patients with connective tissue diseases and cancer reporting toxicity
<table>
<thead>
<tr>
<th>Primary tumour site</th>
<th>Patients with connective tissue disease (n)</th>
<th>Type of connective tissue disease (n)</th>
<th>Study design</th>
<th>Increase in severe acute toxicity</th>
<th>Increase in severe late toxicity</th>
<th>Median radiotherapy dose</th>
<th>Radiotherapy technique</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross et al, 199311</td>
<td>Mixed 61</td>
<td>Rheumatoid arthritis (n=39), systemic lupus erythematosus (n=13), other (n=9)</td>
<td>Matched pair analysis</td>
<td>No</td>
<td>No</td>
<td>56 Gy</td>
<td>External-beam radiotherapy, brachytherapy</td>
<td>No effect</td>
</tr>
</tbody>
</table>
| Morris et al, 199712 | Mixed 209 | Rheumatoid arthritis (n=131), systemic lupus erythematosus (n=25), other (n=53) | Retrospective | No | Yes | 45 Gy | External-beam radiotherapy | Inconclusive*

<p>| Chen et al, 200113 | Breast 36 | Rheumatoid arthritis (n=17), systemic lupus erythematosus (n=5), scleroderma (n=4), other (n=10) | Matched pair analysis | Yes | Yes | 64 Gy | External-beam radiotherapy, brachytherapy | No effect (effect in scleroderma) |
| Phan et al, 200314 | Mixed 38 | Systemic lupus erythematosus (n=21), scleroderma (n=2), other (n=15) | Matched pair analysis | No | No | 55·17 Gy | External-beam radiotherapy, brachytherapy | No effect (effect in scleroderma) |
| Liu et al, 200415 | Prostate 15 | NA | Prospective | No | Yes | 66 Gy | External-beam radiotherapy | Effect |
| Benk et al, 200516 | Mixed 38 | Systemic lupus erythematosus (n=38; 4 radiotherapy treated) | Retrospective | No | No | NA | NA | No effect |
| Gold et al, 200717 | Mixed 20 | Scleroderma (n=20) | Retrospective | No | No | 36 Gy | External-beam radiotherapy, brachytherapy | No effect |
| Lin et al, 200818 | Mixed 73 | Rheumatoid arthritis (n=53), systemic lupus erythematosus (n=13), scleroderma | Retrospective | No | Yes | NA | External-beam radiotherapy | No effect (effect unknown in pelvic site systemic lupus erythematosus or... |</p>
<table>
<thead>
<tr>
<th>Primary tumour site</th>
<th>Patients with connective tissue disease (n)</th>
<th>Type of connective tissue disease (n)</th>
<th>Study design</th>
<th>Increase in severe acute toxicity</th>
<th>Increase in severe late toxicity</th>
<th>Median radiotherapy dose</th>
<th>Radiotherapy technique</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gold et al, 2008¹⁹</td>
<td>Mixed 41</td>
<td>Progressive systemic sclerosis (n=20), systemic lupus erythematosus (n=21)</td>
<td>Retrospective</td>
<td>NA</td>
<td>No</td>
<td>NA</td>
<td>External-beam radiotherapy, brachytherapy</td>
<td>Inconclusive’</td>
</tr>
<tr>
<td>Pinn et al, 2008²⁰</td>
<td>Mixed 21</td>
<td>Systemic lupus erythematosus (n=21)</td>
<td>Retrospective</td>
<td>Yes</td>
<td>No</td>
<td>49.75 Gy</td>
<td>External-beam radiotherapy, brachytherapy, intensity-modulated radiotherapy</td>
<td>No effect</td>
</tr>
<tr>
<td>Patel et al, 2012²¹</td>
<td>Mixed 12</td>
<td>Discoid lupus erythematosus (n=12)</td>
<td>Retrospective</td>
<td>No</td>
<td>No</td>
<td>69 Gy</td>
<td>External-beam radiotherapy, brachytherapy</td>
<td>No effect</td>
</tr>
</tbody>
</table>

Table 2. Effect of connective tissue diseases on toxicity after cancer treatments reported in retrospective and matched pair studies

Figure 1: Main immune cells, interleukins, and cytokines involved in immune surveillance TGF=transforming growth factor. IFN=interferon. IL=interleukin. TNF=tumour necrosis factor
Figure 2: Tumour-cell mechanisms against the immune system. TGF=transforming growth factor, CXC=CXC chemokine, IFN=interferon, IL=interleukin, TNF=tumour necrosis factor.